Skip to main content

Table 1 Clinical, medical, and procedural characteristics

From: Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study

Characteristics

VASP-guided group

Control group

P-value

 

(n = 241)

(n = 240)

 

Age (y)

64.4 ± 3.2

62.8 ± 4.3

0.58

Age ≥ 75 years

61(25.3)

64(26.7)

0.72

Men

128(53.4)

122(50.8)

0.62

BMI (kg/m2)

26.7 ± 4.2

25.3 ± 2.1

0.88

Current Smoker

87(36.2)

96(40.1)

0.55

AF category

 Paroxysmal

92(38.4)

96(40.2)

0.7

 Persistent/permanent

123(51.3)

119(49.7)

0.84

 Unknown

26(10.3)

25(10.1)

0.98

Medical history

 Diabetes

68(28.4)

75(31.3)

0.43

 Hypertension

141(58.8)

144(60.3)

0.57

 Previous heart failure

41(17.1)

52(21.9)

0.19

 Previous stroke or

25(10.3)

28(11.6)

0.65

 thromboembolism

   

 Previous bleeding

16(6.7)

13(5.5)

0.53

CHA2DS2 -VASc Score

3.7 ± 0.6

3.8 ± 0.9

0.87

CHA2DS2 -VASc Score ≥ 2

174(72.4)

168(70.3)

0.35

HAS-BLED Score

3.1 ± 0.4

3.3 ± 0.5

0.76

HAS-BLED Score ≥ 3

61(25.3)

59(24.8)

0.64

LVEF

52.3 ± 4.4

51.0 ± 3.9

0.59

Treatment on admission

 Previous aspirin

31(12.8)

33(14.0)

0.21

 Previous clopidogrel

13(5.4)

14(7.3)

0.48

 Previous oral anticoagulation

131(54.3)

119(49.7)

0.65

Indication for the catheterisation procedure

 Stable angina

188(78.5)

168(70.2)

0.74

 Silent myocardial ischaemia

52(21.5)

71(29.8)

0.17

Platelet (×109/L)

202 ± 23

183 ± 17

0.28

Cr (μmmol/L)

98.3

89.4

0.13

Mean INR on day of procedure

1.2 ± 0.6

1.3 ± 0.7

0.72

Pharmacotherapy

 RAS inhibitors

212(88.2)

200(83.5)

0.61

 Statins

237(98.3)

237(98.7)

0.98

 β-Blockers

123(51.4)

132(55.3)

0.76

 Digoxin

32(13.4)

41(17.2)

0.25

 Amiodarone

62(25.9)

46(19.4)

0.09

Procedural characteristics

 No. of lesions treated per patient

1.4

1.5

0.88

 No. of stents per patient

1.3

1.2

0.64

 Patients receiving DES

241(100)

240(100)

1

 GP IIb/IIIa inhibitors

61(25.4)

67(28.1)

0.38

  1. Values are presented as mean ± SD or n (%)
  2. AF atrial fibrillation, BMI body mass index, Cr creatinine, GP glycoprotein, INR international normalised ratio, LVEF left ventricular ejection fraction, RAS renin-angiotensin system